News
Contact Us
Attn: Ann Sun
Tel: +86-532-81926227
Fax: +86-532-81926219
Email: sales@marine-oligo.com
Industry Trends

Location:Home > News Room > Industry Trends >

Effect of chitooligosaccharide on hepatic triglyceride metabolism and related mechanisms

Posted by:bozhihuili    Published:2016-03-25 14:50

Zhonghua Gan Zang Bing Za Zhi. 2016 Mar 20;24(3):220-4. doi: 10.3760/cma.j.issn.1007-3418.2016.03.012.


Effect of chitooligosaccharide on hepatic triglyceride metabolism and related mechanisms

[Article in Chinese]


Wang J1, Jiang M2, Xin YN3, Geng N4, Li XJ5, Xuan SY3.


Abstract:
OBJECTIVE:
To investigate the effect of chitooligosaccharide (COS) on hepatic triglyceride (TG) metabolism and 

related mechanisms.


METHODS:
The LO2 cells treated by 1 mmol/L fatty acid were used as model group, the cells treated by 1 mmol/L 

fatty acid and 0.5 mg/ml COS were used as COS group, and the untreated cells were used as control 

group. The TG content in cells was measured. RT-PCR and Western blot were used to measure the 

mRNA and protein expression of sterol regulatory element binding protein-1c (SREBP-1c), fatty acid 

synthase (FAS), and carnitine palmityl transferase 1A (CPT1A) in each group. Male C57BL/6J mice were 

randomized into control group, high-fat group, and COS group to receive different treatments. Sixteen 

weeks later, the liver was harvested for HE and oil red O staining to measure the content of TG in the 

liver. The t-test or one-way analysis of variance was used for comparison of data between groups, 

and the SNK method was used for comparison of data between any two groups.

RESULTS:
The LO2 cells in the model group had an increased number of lipid droplets and an increased TG 

content, and after COS treatment, the TG content was low. The COS group had significantly lower 

relative mRNA expression of SREBP-1c and FAS compared with the model group (1.135 ± 0.177 

vs 2.322 ± 0.198,F= 60.457,P< 0.01; 1.226 ± 0.150 vs 1.801 ± 0.159,F= 24.753,P< 0.01), while 

compared with the control group, the COS group had significantly higher mRNA expression of 

CPT1A (1.254 ± 0.156 vs 1.908 ± 0.087,F= 31.734,P< 0.01). The COS group had significantly 

lower protein expression of SREBP-1c and FAS than the model group (0.161 ± 0.081 vs 0.351±0.016,

F= 188.920,P< 0.01; 0.332 ± 0.023 vs 1.238 ± 0.051,F= 624.069,P< 0.01), and significantly higher 

protein expression of CPT1A than the model group (1.014 ± 0.033 vs 0.561 ± 0.046,F= 193.793,

P< 0.01). COS reduced the TG content in the liver in rats on high-fat diet.


CONCLUSION:
COS can reduce the accumulation of TG in the hepatocyte model of nonalcoholic fatty liver disease 

and in the liver in rats on high-fat diet, and the possible mechanism may be related to inhibiting the 

expression of SREBP-1c and downstream FAS, reducing the synthesis of TG, increasing the expression 

of CPT1A, and accelerating the breakdown of TG.

PMID: 27095767 [PubMed - in process]


Origin: http://www.ncbi.nlm.nih.gov/pubmed/27095767


Copyright©Qingdao BZ Oligo Biotech Co., Ltd  Tel:0532-81926227  Fax:0532-81926219  DesDev Inc.
Headquarter:Room 806, D&D Fortune Center, No. 182-6 Haier Road, Qingdao 266061, China